Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 3Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 21Other solid neoplasm 4Thoracic 3Head & Neck 3Gynecologic 3Other hematologic neoplasm 2Gastrointestinal 2Dermatologic 2Tumor-Agnostic 1Sarcoma 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Liposarcoma, Myxoid 1Liposarcoma 1

Interventions

Temozolomide 33Radiotherapy 32pembrolizumab 18Cyclophosphamide 18Irinotecan 16Gemcitabine 16Doxorubicin 16Nivolumab 11Docetaxel 11Sirolimus 10Imatinib Mesylate 10Ifosfamide 10Filgrastim 10Radiation 9Bevacizumab 9Vincristine 8Carboplatin 8pazopanib 7Everolimus 7temsirolimus 6atezolizumab 6Peripheral Blood Stem Cell Transplantation 6Etoposide 6fludarabine phosphate 5Vorinostat 5Specimen Handling 5Radiotherapy, Conformal 5PM 01183 5Ipilimumab 5Erlotinib Hydrochloride 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × palbociclib × Sarcoma × Clear all
NCT06843967 2026-05-22

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
54 enrolled
Sarcoma

Liposarcoma, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡